A股異動 | 康芝藥業(300086.SZ)觸及漲停 簽署注射用蘇拉明鈉研究合作協議
格隆匯2月15日丨康芝藥業(300086.SZ)直線拉昇觸及漲停,現報7.51元,成交額放大至3.79億元,總市值33.5億元。公司與廣東省公共衞生研究院簽署注射用蘇拉明鈉研究合作協議,委託廣東省公共衞生研究院進行蘇拉明鈉對不同SARS-CoV-2病毒變異株的抑制藥效及其最低藥效濃度研究。據悉,公司本次合作協議是考慮到當下新冠病毒株突變愈加頻繁,亟需找到一種廣譜型新冠病毒特效藥。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.